Insulet (NASDAQ:PODD) Given New $200.00 Price Target at Sanford C. Bernstein

Insulet (NASDAQ:PODD) had its price objective raised by Sanford C. Bernstein from $175.00 to $200.00 in a research note released on Thursday,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

PODD has been the subject of a number of other research reports. Wells Fargo & Company boosted their price target on Insulet from $144.00 to $172.00 and gave the stock an “equal weight” rating in a research report on Thursday. Robert W. Baird set a $175.00 target price on shares of Insulet in a research report on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price target on shares of Insulet in a research report on Wednesday. Barclays raised Insulet to a “hold” rating in a research report on Wednesday, October 7th. Finally, Canaccord Genuity Group lowered their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $192.36.

Insulet Price Performance

NASDAQ PODD opened at $156.12 on Thursday. The company has a 50 day simple moving average of $141.91 and a 200-day simple moving average of $177.34. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of 25.43, a price-to-earnings-growth ratio of 1.25 and a beta of 1.06. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The company had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter last year, the business posted $1.24 EPS. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. Equities research analysts predict that Insulet will post 6.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

Several large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Insulet in the 2nd quarter valued at $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its position in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Amundi grew its stake in Insulet by 14.4% during the first quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock worth $93,781,000 after buying an additional 56,225 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Insulet by 40.5% during the first quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock worth $89,392,000 after buying an additional 122,720 shares in the last quarter. Finally, Man Group plc bought a new position in shares of Insulet in the second quarter valued at approximately $78,746,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.